INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update
03 nov. 2021 16h15 HE
|
INmune Bio, Inc.
Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) Cash and cash equivalents of $84.5 million...
INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting
27 oct. 2021 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3
25 oct. 2021 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, Oct. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s...
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series
27 sept. 2021 16h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences
20 sept. 2021 16h00 HE
|
INmune Bio, Inc.
BOCA RATON, Florida, Sept. 20, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination
01 sept. 2021 16h00 HE
|
INmune Bio, Inc.
Company to present additional phase 1b data during webinar on Sept 7th, 2021 at 4:30 pm EST. Boca Raton, FL, Sept. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a...
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells
25 août 2021 16h00 HE
|
INmune Bio, Inc.
First positive clinical confirmation of in vivo NK response, mirroring in vitro data Boca Raton, FL, Aug. 25, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a...
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
10 août 2021 09h00 HE
|
INmune Bio, Inc.
BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference
05 août 2021 08h15 HE
|
INmune Bio, Inc.
LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update
04 août 2021 16h20 HE
|
INmune Bio, Inc.
BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...